1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation
  4. >>Legislation

Cosmetics Reform In, Dietary Supplements Out Of US Omnibus Spending Bill

 
• By Lauren Nardella

The must-pass federal spending bill includes the Modernization of Cosmetics Regulation Act, which previously appeared as a rider in US Food and Drug Administration user-fee legislation but was cut from the final iteration.

Provisions that would overhaul the US Food and Drug Administration’s oversight of the cosmetics industry have made the cut in an omnibus bill to fund the government in 2023, moving the long-awaited reforms tantalizingly close to the finish line.

Released 20 December, the Consolidated Appropriations Act of 2023 is a massive, sprawling spending bill that directs $1.7 trillion in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

Senate HELP Committee Adds Sunscreen Regulation Overhaul To OMUFA Reauthorization

 
• By Lauren Nardella

OMUFA reauthorization bill including amendment with sunscreen regulation provisions passed by Senate committee, which also approved other provisions not included in House OMUFA bill.

Sunscreen Regulation Reforms Still Could Hitch Ride On Senate OMUFA Reauthorization Bill

As stakeholders and lawmakers pin their hopes on OMUFA reauthorization as a vehicle for enacting sunscreen regulatory changes, Senate version of the bill could be the ticket after a sunscreen-specific amendment withdrawn in the House.

Unanimous Support Across House Energy And Commerce To Reauthorize FDA’s OMUFA Program

 
• By Malcolm Spicer

Committee voted 51-0 to approve five-year authorization of FDA program user fee program needed to support regulatory pathway for large majority of nonprescription drugs available in the US with amendment to expand stakeholder engagement with FDA.

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

More from Policy & Regulation

Producers Sue Oregon Over ‘Crushing’ EPR Recycling Law, Call It Unconstitutional

 
• By Eileen Francis

A national wholesalers’ trade group is suing Oregon, claiming its EPR law, which requires producers to register, report packaging data and pay fees, is unconstitutional and overly burdensome.

Senate HELP Committee Adds Sunscreen Regulation Overhaul To OMUFA Reauthorization

 
• By Lauren Nardella

OMUFA reauthorization bill including amendment with sunscreen regulation provisions passed by Senate committee, which also approved other provisions not included in House OMUFA bill.

Sunscreen Regulation Reforms Still Could Hitch Ride On Senate OMUFA Reauthorization Bill

As stakeholders and lawmakers pin their hopes on OMUFA reauthorization as a vehicle for enacting sunscreen regulatory changes, Senate version of the bill could be the ticket after a sunscreen-specific amendment withdrawn in the House.